Drug intelligence / Profile preview

IOA-359

Development stage: Preclinical
Lead developer: iOnctura
Modality: Small Molecules
Administration: Oral

Overview

IOA-359 is a novel, orally available small molecule inhibitor of the TGF-β pathway, specifically targeting the Transforming growth factor beta receptor 1 (also known as ALK5). Developed by iOnctura through an agreement with Clavius Pharmaceuticals, IOA-359 is designed to block the immunosuppressive effects of TGF-β within the tumor microenvironment, thereby potentially enhancing anti-tumor immune responses and inhibiting tumor growth and metastasis. The compound is currently in preclinical development for the treatment of solid tumors, acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS).

Targets

TGFBR1

Beyond the preview

Go deeper on IOA-359.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IOA-359.

Explore the full profile